Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Goldstein

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Journal of Medical Genetics|March 29, 2011
The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesisFanny Kortüm, Soma Das, Max Flindt, et al.
JAMA Psychiatry|October 17, 2014
Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP studyChristoph U Correll, Delbert G Robinson, Nina R Schooler, et al.
Journal of Inherited Metabolic Disease|September 6, 2017
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trialMelanie B Gillingham, Stephen B Heitner, Julie Martin, et al.
Journal of Patient-Reported Outcomes|October 27, 2025
Signs, symptoms, and health-related quality of life in MELAS: measuring what's important from the patient and clinician perspectivesPaolo Medrano, Benjamin Banderas, Marisa Brimmer, et al.
Neurology|January 4, 2020
Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trialKaren L Madsen, Astrid E Buch, Bruce H Cohen, et al.
Human Genetics|June 21, 2013
The mitochondrial solute carrier SLC25A5 at Xq24 is a novel candidate gene for non-syndromic intellectual disabilityJoke Vandewalle, Marijke Bauters, Hilde Van Esch, et al.
The American Journal of Psychiatry|March 3, 2015
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP studyDelbert G Robinson, Nina R Schooler, Majnu John, et al.
Molecular Genetics and Metabolism|June 18, 2016
Solid organ transplantation in primary mitochondrial disease: Proceed with cautionSumit Parikh, Amel Karaa, Amy Goldstein, et al.
Journal of Inherited Metabolic Disease|October 6, 2017
Erratum to: Common data elements for clinical research in mitochondrial disease: a National Institute for Neurological Disorders and Stroke projectAmel Karaa, Shamima Rahman, Anne Lombès, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 18, 2023
Optimized Nutrition in Mitochondrial Disease Correlates to Improved Muscle Fatigue, Strength, and Quality of LifeDonna DiVito, Amanda Wellik, Jessica Burfield, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Journal of Medical Genetics|March 29, 2011
The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesisFanny Kortüm, Soma Das, Max Flindt, et al.
JAMA Psychiatry|October 17, 2014
Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP studyChristoph U Correll, Delbert G Robinson, Nina R Schooler, et al.
Journal of Inherited Metabolic Disease|September 6, 2017
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trialMelanie B Gillingham, Stephen B Heitner, Julie Martin, et al.
Journal of Patient-Reported Outcomes|October 27, 2025
Signs, symptoms, and health-related quality of life in MELAS: measuring what's important from the patient and clinician perspectivesPaolo Medrano, Benjamin Banderas, Marisa Brimmer, et al.
Neurology|January 4, 2020
Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trialKaren L Madsen, Astrid E Buch, Bruce H Cohen, et al.
Human Genetics|June 21, 2013
The mitochondrial solute carrier SLC25A5 at Xq24 is a novel candidate gene for non-syndromic intellectual disabilityJoke Vandewalle, Marijke Bauters, Hilde Van Esch, et al.
The American Journal of Psychiatry|March 3, 2015
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP studyDelbert G Robinson, Nina R Schooler, Majnu John, et al.
Molecular Genetics and Metabolism|June 18, 2016
Solid organ transplantation in primary mitochondrial disease: Proceed with cautionSumit Parikh, Amel Karaa, Amy Goldstein, et al.
Journal of Inherited Metabolic Disease|October 6, 2017
Erratum to: Common data elements for clinical research in mitochondrial disease: a National Institute for Neurological Disorders and Stroke projectAmel Karaa, Shamima Rahman, Anne Lombès, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 18, 2023
Optimized Nutrition in Mitochondrial Disease Correlates to Improved Muscle Fatigue, Strength, and Quality of LifeDonna DiVito, Amanda Wellik, Jessica Burfield, et al.
Pageof 11